August 20, 2014 01:33 PM EDT 0 comments

New Wall Street Journal Editorial Calls the Demand to Reduce Drug Prices a “Medical Innovation Threat”

An editorial published yesterday in the Wall Street Journal argues that calls to reduce prices of new drugs is the latest threat to medical innovation. With pharmaceutical companies subject to a seemingly endless approval process and a narrow window of profitability before their patents lapse (resulting in affordable generic drugs which now account for 86% of total filled prescriptions), the piece claims that the ability to set their own prices is a key motivating force in driving medical innovation.

Read More

August 18, 2014 03:21 PM EDT 0 comments

Patient Advocacy Groups: Despite the Affordable Care Act, Insurers Still Working to Limit Patient Drug Access

A strongly worded letter to Health and Human Services Secretary Sylvia Mathews Burwell, signed by more than 300 patient advocacy groups, accuses insurance providers of employing discriminatory policies designed to limit patient access to certain essential drugs – despite the provisions outlined in the Affordable Care Act.

Read More

August 18, 2014 01:43 PM EDT 0 comments

Forbes: Medical Innovation is Key to Containing Rising Healthcare Costs

Innovative treatments not only save lives – they save money. A newly published editorial in Forbes by pharmaceutical executive and chemist John Lechleiter illustrates how past medical triumphs, such as the Salk polio vaccine and anti-retroviral treatments for HIV, effectively curbed escalating costs.

Read More

August 5, 2014 11:41 AM EDT 0 comments

Outdated Coverage Policies in Maine No Longer Limit Cancer Patients' Access to Life-Saving Medications!

Until now, cancer patients in Maine (as in several other states and those covered by federal policies) who have wanted to utilize oral chemotherapy treatments have faced substantially higher co-pays than the intravenous option.

Read More

August 4, 2014 05:52 PM EDT 0 comments

Forbes: Politicians Shouldn't Question Drug Costs But Rather Their Value.

A recent article in Forbes Magazine says politicians shouldn't question drug costs, but consider “the value that the drug brings to healthcare in terms of: 1) saving lives; 2) mitigating pain/suffering and improving the quality of life for patients; 3) reducing overall healthcare costs." In other words, our lives ARE worth it.

Read More